A clinical study to learn about the safety and effects of KIN-2787, a new oral anticancer drug for the treatment of patients with BRAF and/or NRAS Mutation-positive Solid Tumors
KN-8701/KIN2787CI101
Phase 1 other active
Quick answer
A clinical study to learn about the safety and effects of KIN-2787, a new oral anticancer drug for the treatment of patients with BRAF and/or NRAS Mutation-positive Solid Tumors for Participants with BRAF and/or NRAS mutation positive tumors is a Phase 1 program (other) at Pierre Fabre Medicament with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pierre Fabre Medicament
- Indication
- Participants with BRAF and/or NRAS mutation positive tumors
- Phase
- Phase 1
- Modality
- other
- Status
- active